Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
about
Androgen receptor molecular biology and potential targets in prostate cancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerComparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.Androgen deprivation therapy for prostate cancer-review of indications in 2010Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Safety of antiandrogen therapy for treating prostate cancer.Management of complications of androgen deprivation therapy in the older man.Controversies surrounding androgen deprivation for prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.The course of metastatic prostate cancer under treatment.Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesA Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.Prostate cancer clinical trial end points: "RECIST"ing a step backwards.Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic reviewCombination hormonal therapy: a reassessment within advanced prostate cancer.Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Leuprolide acetate: a drug of diverse clinical applications.The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?Use of androgen deprivation therapy in prostate cancer: indications and prevalence.Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.Cardiovascular toxicities of systemic treatments of prostate cancer.Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.Use of combined androgen blockade for advanced prostate cancer in British Columbia.Recent discoveries and developments of androgen receptor based therapy for prostate cancer
P2860
Q24602861-EBF1BBF8-3212-43C3-BDEA-DC1A4098F72AQ26747782-DF33E920-3486-43C9-ABCB-AFA47102DB4CQ30010969-2E1446C0-FD1A-4EB4-B367-0EAC78C162F3Q33765455-A990620D-42EB-4C64-B145-65ABA021B6A4Q34111603-52B5E6F7-8E42-4999-99B6-6D45E53388E0Q34437308-68CEB98C-947E-41E7-A0D6-40705980B772Q34441134-247878D5-22A5-43C4-8498-6ECACCC2A321Q34782101-ADB5BF30-CF60-4973-A973-70DC5435ACDEQ34849222-5DFBC16F-5061-443A-BC79-15E66CBCF17EQ34997355-093DD5BC-2BF2-4429-84F7-A8BCEFE76D21Q35059214-A02AF042-04F0-4EE9-8AC4-BCD087F2C0CAQ35569303-D5EEADEE-CE16-4006-9575-02FB965D089EQ35743429-9E6897E6-BA8C-438E-9EAD-45CAB9AAE5ABQ35751894-3E00B880-1A54-4986-A9ED-8B16C6D75CDEQ35840364-11D45FE8-DD77-48B4-BA8F-1AEF1B3146D8Q35886568-BA84BF11-CE74-4128-A6B7-ED83CF4AFD28Q36039229-8BA4941B-2765-4BD0-83EC-5393F7C57EF2Q36381291-85271A24-6157-4F93-A502-E9DF808D6198Q36985884-5A5D3FCD-893A-47EF-94FC-CF739659DB21Q37074125-3F1EE912-CD1F-4D0A-BF2C-07A153D3376BQ37074379-18974564-FABA-4DD1-BA6C-85E7CE930F62Q37741773-CA8F990E-F20E-4E14-B338-F04F8E18AA41Q38130174-68F8223C-41BB-4572-B266-AFE63E3DE55CQ39002111-69A2A277-2A69-4A6C-BE2B-0E1882322CC7Q42857879-EE4AF43F-96FA-414E-BE49-89814B0AC856Q43427594-AE4CA761-CAD2-4D8C-966A-92627436F53CQ44534598-0BA33B75-4484-4399-84B3-07E831EA5E20Q46694974-00C64F67-7255-4AA6-B7C8-B316E59E07FAQ46990082-2D2E615F-46F8-4054-9D73-7EE454F0ADD0Q48629219-DEA03DEB-6717-4270-A36B-2CEA764851B4Q48724046-6C52EAB2-E132-46F1-A6E0-EC4E652EEFE4Q51133487-1FB4B873-D1A9-40F0-B30C-8354688C3CF4Q56621622-C759309F-20D4-48D0-837C-99CF42CD3BE0
P2860
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Combined androgen blockade wit ...... e cancer: a systematic review.
@ast
Combined androgen blockade wit ...... e cancer: a systematic review.
@en
Combined androgen blockade wit ...... e cancer: a systematic review.
@nl
type
label
Combined androgen blockade wit ...... e cancer: a systematic review.
@ast
Combined androgen blockade wit ...... e cancer: a systematic review.
@en
Combined androgen blockade wit ...... e cancer: a systematic review.
@nl
prefLabel
Combined androgen blockade wit ...... e cancer: a systematic review.
@ast
Combined androgen blockade wit ...... e cancer: a systematic review.
@en
Combined androgen blockade wit ...... e cancer: a systematic review.
@nl
P2093
P31
P1433
P1476
Combined androgen blockade wit ...... e cancer: a systematic review.
@en
P2093
Bennett CL
Crawford ED
Schellhammer PF
P304
P356
10.1016/S0090-4295(00)01086-4
P407
P577
2001-04-01T00:00:00Z